We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Cocoa Flavanols vs Semaglutide: Semaglutide has the stronger overall evidence (8.5 vs 5/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Semaglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
0 of 1 studies with measurable effects showed benefit.
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (1)
Outcomes where both Cocoa Flavanols and Semaglutide have evidence — compare verdict strength side-by-side.
200-500 mg cocoa flavanols daily (COSMOS used 500 mg a day). A cited dose-response meta-analysis put the peak endothelial benefit near 710 mg, above the highest dose in the cited trials.
Any time of day
Standardized cocoa flavanol extract (epicatechin-standardized)
Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.
Any time of day
Subcutaneous once-weekly injection (Ozempic / Wegovy)
2-8 weeks
Acute to 8 weeks
Years
Throughout use
Weeks to months
Months (titrated over 16-20 weeks)
Months to years
Especially during dose escalation
Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial.
Am J Clin Nutr (2022) · Rct · n=21442
21,442 older US adults, 500mg flavanols/day, median 3.6 years, double-blind placebo-controlled
Effect of cocoa on blood pressure.
Cochrane Database Syst Rev (2017) · Meta analysis
Cochrane meta-analysis of flavanol-rich cocoa vs control
Dose-response relationship between cocoa flavanols and human endothelial function: a systematic review and meta-analysis of randomized trials.
Food Funct (2019) · Meta analysis
15 articles, 18 intervention arms pooled
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).
N Engl J Med (2021) · Rct · n=1961
Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).
N Engl J Med (2023) · Rct · n=17604
Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).
N Engl J Med (2016) · Rct · n=3297
Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks
Semaglutide has a higher evidence score (8.5/10 vs 5/10) and wins in 2 of 3 categories.
For support heart health, Semaglutide has a higher relevance score (75 vs 58).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.